MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together
with MIL62 and how well this combination works in treating patients with Relapsed/Refractory
low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus
lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).